Is newer always better? Re-evaluating the benefits of newer pharmaceuticals

▶ One highly cited prior research article suggesting newer drugs “pay for themselves” is fundamentally flawed. ▶ Similar modelling strategies for antihypertensives run counter to established clinical trial evidence. ▶ Studies that do not adequately control for unobserved characteristics that jointly determine drug choice and health expenditures are likely subject to significant bias.